Evidence for kinase inhibitor activity in acute myeloid leukaemia

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

Does the patient with myelofibrosis feel better through pacritinib?

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

Treatment and survival of patients with chronic myeloid leukaemia in Europe

PM1183 plus doxorubicin shows interesting activity in small cell lung cancer

Expert overview on the recent developments in mantle cell lymphoma

Round-up of the latest research on lung cancer

Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma